6076194 Health, Department of - Notice of Emergency and Proposed Rulemaking - Re-scheduling of and additions to the schedules of controlled substances
-
DEPARTMENT OF HEALTH
NOTICE OF EMERGENCY AND PROPOSED RULEMAKING
The Director of the Department of Health (Director), pursuant to the authority set forth in § 201(a) of the District of Columbia Uniform Controlled Substances Act of 1981, effective August 5, 1981 (D.C. Law 4-29; D.C. Official Code § 48-902.01 (2014 Repl. & 2015 Supp.)), and Mayor's Order 98-49, dated April 15, 1998, hereby gives notice of the adoption, on an emergency basis, of the following amendments to Chapter 12 (Controlled Substances Act Rules) of Title 22 (Health), Subtitle B (Public Health and Medicine) of the District of Columbia Municipal Regulations (DCMR).
The emergency and proposed rules would update the list of Schedules I, II, and IV drugs, and were adopted after considering the eight (8) factors set forth in Section 201(a) of the Act (D.C. Official Code § 48-902.01 (2014 Repl. & 2015 Supp.)).
Emergency action is necessary because the updated list includes cannabimimetic drugs that have no legitimate medical use, are readily available, and pose an immediate risk to public health and safety because of their harmful effects when abused. This rulemaking incorporates substances identified with the cooperation of the government of China. Those effects of abuse include vomiting, anxiety, agitation, irritability, seizures, hallucinations, tachycardia, elevated blood pressure, and loss of consciousness.
The Emergency rules were adopted by the Director on May 9, 2016, became effective immediately, and shall expire on September 6, 2016.
The Director also gives notice of the intent to take final rulemaking action in not less than thirty (30) days after the date of publication of this notice in the District of Columbia Register.
Chapter 12, CONTROLLED SUBSTANCES ACT RULES, of Title 22-B DCMR, PUBLIC HEALTH AND MEDICINE, is amended as follows:
Section 1201, SCHEDULE I ENUMERATED, is amended as follows:
Subsection 1201.1(c) is amended by striking the word “and” at the end of paragraph (45) and adding new paragraphs to be numbered (47) through (227) as follows:
(47) (2C-T) 2-(2,5-dimethoxy-4-(methylthio)phenyl)ethanamine; OR 4-methylthio-2,5-dimethoxyphenethylamine;
(48) 4- methylthio-2,5-dimethoxyphenethylamine;
(49) (2C-B-butterFLY) 2-(10-Bromo-2,3,4,7,8,9 hexahydropyrano[2,3-g]chromen-5-yl)ethanamine;
(50) (2C-B-FLY) 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4- yl)ethanamine;
(51) (2C-B-hemiFLY, 2CB-5- hemiFLY) 2-(7-Bromo-5-methoxy-2,3-dihydro-1-benzofuran-4- yl)ethanamine;
(52) (2C-B-FLY-NBOMe) N-(2-Methoxybenzyl)-1-(8-bromo-2,3,6,7- tetrahydrobenzo[1,2-b:4,5-b']difuran-4-yl)-2-aminoethane;
(53) (2C-B-NBOMe, 2,5B-NBOMe) 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine; OR 2,5-Dimethoxy-4- bromo-N-(2-methoxybenzyl) phenethylamine
(54) 2CBCB-NBOMe N-(2-methoxybenzyl)-1-[(7R)-3-bromo-2,5-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methanamine;
(55) 2C-C-NBOMe, 2,5C-NBOMe 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine; OR 2,5-Dimethoxy-4-chloro-N-(2-methoxybenzyl)phenethylamine;
(56) 2C-H-NBOMe, 2,5H-NBOMe 2-(2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine;
(57) 2C-I-NBOH, 2,5I-NBOH N-(2-Hydroxybenzyl)-4-iodo-2,5-dimethoxyphenethylamine;
(58) 2C-I-NBOMe, 2,5INBOMe, 2,5I-NBOMe, 25I-NBOMe, NBOMe-2C-I, BOM-CI 2- 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine; OR 2,5-Dimethoxy-4-iodo-N-(2-methoxybenzyl)phenethylamine;
(59) (2CBCB-NBOMe) N-(2-methoxybenzyl)-1-[(7R)-3-bromo-2,5- dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methanamine
(60) (2C-H-NBOMe, 2,5H-NBOMe) 2-(2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
(61) (2C-I-NBOH, 2,5I-NBOH) N-(2-Hydroxybenzyl)-4-iodo-2,5-dimethoxyphenethylamine;
(62) 2C-TFM-NBOMe) 2-(4-trifluoromethyl-2,5-dimethoxyphenyl)-N-[(2-ethoxyphenyl)methyl]ethanamine;
(63) (25I-NBF) 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2- fluorophenyl)methyl]ethanamine;
(64) (25I-NBMD, NBMD-2C-I, Cimbi-29) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2,3ethylenedioxyphenyl)methyl]ethanamine;
(65) (3C-B-FLY) 2-(4-bromo-2,3,6,7-tetrahydrofurobensofuran-8-yl)-1- methyl-ethylamine;
(66) (4-CAB, AEPCA) 4-Chlorophenylisobutylamine; OR 1-(4-chlorophenyl)butan-2-amine; OR 4-chloro-α-ethylphenethylamine;
(67) (4-FA, PAL-303, Flux, Flits, R2D2) para-fluoroamphetamine; OR 4-fluoroamphetamine; OR (RS)-1-(4-Fluorophenyl)propan-2-amine;
(68) (5-APB) 5-(2-Aminopropyl)benzofuran;
(69) (5-APDB) 5-(2-Aminopropyl)-2,3-dihydrobenzofuran; 1-(2,3-dihydro-1-benzofuran-5-yl)propan-2-amine; 5-(2-Aminopropyl)-2,3-dihydrobenzofuran (3-Desoxy-MDA, EMA-4)
(70) (6-APB; Benzofury) 6-(2-aminopropyl)benzofuran; OR 1-benzofuran-6-ylpropan-2-amine;
(71) (6-APDB) 6-(2-Aminopropyl)-2,3,-dihydrobenzofuran;
(72) (APB) ((2-aminopropyl)benzofuran); OR [(2- aminopropyl)benzofuran]; OR (2-aminopropyl)benzofuran;
(73) (APDB) ((2-aminopropyl)-2,3-dihydrobenzofuran); OR [(2- aminopropyl)-2,3-dihydrobenzofuran]; OR (2-aminopropyl)- 2,3-dihydrobenzofuran;
(74) (bromo-dragonFLY) 1-(4-Bromofuro[2,3-f][1]benzofuran-8-yl)propan-2-amine; OR bromo-benzodifuranyl-isopropylamine;
(75) (DOB) 2,5-Dimethoxy-4-bromoamphetamine; OR 1-(4-Bromo-2,5- dimethoxyphenyl)-2-aminopropane;
(76) (DOC) 2,5-Dimethoxy-4-chloroamphetamine; OR 1-(4-chloro-2,5- dimethoxy-phenyl)propan-2-amine; OR 4-chloro-2,5- dimethoxyamphetamine;
(77) (DOI) 2,5-dimethoxy-4-iodoamphetamine; OR 1-(2,5-dimethoxy-4- iodophenyl)-propan-2-amine; OR 4-iodo-2,5- dimethoxyamphetamine;
(78) DOM, STP 4-methyl-2,5-dimethoxy-amphetamine; OR 4-methyl-2,5-dimethoxy-a-methylphenethylamine;
(79) (Fluoroamphetamine);
(80) MDA 3,4-methylenedioxy amphetamine;
(81) MDMA 3,4-methylenedioxymethamphetamine;
(82) MDE, MDEA3,4-methylenedioxy-N-ethylamphetamine; OR N-ethylalpha-methyl-3,4(methylenedioxy)phenethylamine;
(83) Mescaline 3,4,5-trimethoxyphenethylamine;
(84) (Mescaline-NBOMe) N-(2-Methoxybenzyl)-2-(3,4,5- trimethoxyphenyl)ethanamine; OR 3,4,5-trimethoxy-N-(2- methoxybenzyl)phenethylamine;
(85) (PMMA, 4-MMA) para-Methoxy-N-methylamphetamine; OR 4-methoxy-N- methylamphetamine; OR 1-(4-methoxyphenyl)-N-methyl- propan-2-amine;
(86) TMA, 3,4,5-trimethoxyamphetamine;
(87) 2,5-Dimethoxy-4-ethylamphetamine, (DOET, DOE);
(88) Eticyclidine (PCE, CI-400);
(89) N-Ethyl-mda; Eve (amphetamine); 3,4-Methylenedioxyethylamphetamine; 3,4-Methylenedioxy-N-ethylamphetamine;
(90) 4-Methylthioamphetamine (4-MTA);
(91) 2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2- methoxybenzyl)ethanamine, (2C-B-NBOMe);
(92) 4- Methyl- 2,5-dimethoxyphenethylamine, (2C-D);
(93) 2-(4-Methyl-2,5-dimethoxyphenyl)-N- (2-methoxybenzyl)ethanamine, (2C-D-NBOMe);
(94) 4-Ethyl- 2,5-dimethoxyphenethylamine, (2C-E);
(95) 2-5-Dimethoxy-4-iodo-N-(2-methoxybenzyl)ethanamine, (2C-I-NB0Me);
(96) 1-(Benzofuran-5-yl)-N-methylpropan-2-amine, (5-MAPB) (1-(benzofuran-5-yl)-N-methylpropan-2-amine);
(97) N-Methy\-(6-bromo-3,4- methylenedioxypheny1)propan-2-amine, (6-Br-MDMA);
(98) 1-(6-chloro-1,3-benzodioxol-5-yl)-N-methylpropan-2-amine, 6-Chloro-MDMA (6-Cl-MDMA, 2-Cl-4,5-MDMA);
(99) (AB-FUBINACA) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide;
(100) (ADB-PINACA) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide;
(101) (ADBICA) N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indole-3-carboxamide;
(102) (APICA) N-(1-adamantyl)-1-pentylindole-3-carboxamide;
(103) (CUMYL-THPINACA) N-(2-Phenypropan-2-yl)-1-(tetrahydropyran 4- ylmethyl)-1H-indazole-3-carboxamide;
(104) (EAM-220O1); (5"-fluoro-JWH-210) (1-(5-Flouropentyl)-1H-indol-3-yl)(4-ethylnaphthalen-1-yl)methadone;
(105) (FUB-JWH-018) (1-(4-Fluorobenzyl)-1H-indol-3-yl)(naphthalene-1-yl)methadone;
(106) (FUB-PB-22); (UNII-DS46154N3F); (DS46154N3F) quinolin-8-yl 1-[(4-fluorophenyl)methyl]indole-3-carboxylate;
(107) (MDMB-CHMICA) N-(1-Methoxy-3,3-dimethyl-1-oxobutan-2yl)-1-(cyclohexylmethyl)-1H-indole-3-carboxamide;
(108) (MDMB-FUBINACA) N-(1-Methoxy-3,3-dimethyl-1-oxobutan-2-yl)-1(4-fluorobenzyl)-1H-indazole-3-carboxamide;
(109) (PX-2) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide;
(110) (2-FMC) 1-(2-flourophenyl)-2-methylaminopropan-1-one;
(111) (2-MMC) 1-(2-methylphenyl)-2-methylaminopropan-1-one;
(112) (3,3-DMMC) 1-(3,4- dimethylphenyl)-2-methylaminopropan-1-one;
(113) (3-CMC) 1-(3-chlorophenyl)-2-methylaminopropan-1-one;
(114) (3-MeOMC) 1-(3-methoxyphenylaminopropan-1-one;
(115) (3-MMC) 1-(3-methylphenyl)-2-methylaminopropan-1-one;
(116) (4-BMC) 1-(4-bromophenyl)-2-methylaminopropan-1-one;
(117) (4-CMC) 1-(4-chlorophenyl)- 2-methylaminopropan-1-one;
(118) (4-MMC) 4-methyl methcathinone or 4-methyl ephedrone;
(119) (1-butyl-1H-indol-3-yl)(4-methylnaphthalen-1-yl)methanone;
(120) [1-[(1-methyl-2-piperidinyl)methyl]-1H-indol-3-yl]-1-naphthalenyl-methanone;
(121) 3–(4-methoxyphenyl)–2-methyl-1-[(2–(4-morpholinyl)ethyl)– 1H-indol-3-yl]-methanone;
(122) 2–(3-methoxyphenyl)–1–(1-pentyl-1H-indol-3-yl)-ethanone;
(123) (2-iodophenyl)[1-[(1-methyl-2-piperidinyl)methyl]-1H-indol- 3-yl]-methanone;
(124) [1-[(1-methyl-2-piperdinyl)methyl]-1H-indol-3- yl]tricycle[3.3.1.13,7]dec-1-yl-methanone;
(125) 1-naphthalenyl(1-propyl-1H-indol-3-yl)-methanone;
(126) 5-[3–(1-naphthoyl)–1H-indole-1-yl]pentanenitrile;
(127) 3–(1-naphthenylmethyl)–1-pentyl-1H-indole;
(128) (2-methyl-1-propyl-1H-indol-3-yl)–1-napthalenyl-methanone;
(129) 1-naphthalenyl[1–(4-penten-1-yl)–1H-indol-3-yl]-methanone;
(130) (4-bromonaphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone;
(131) (4-fluoronaphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone;
(132) (2-methyl-1-phenyl-1H-indol-3-yl)–1-naphthalenyl-methanone;
(133) 2–(2-chlorophenyl)–1–(1-pentyl-1H-indol-3-yl)-ethanone;
(134) [1–(5-chloropentyl)–1H-indol-3-yl](2-iodophenyl)- methanone;
(135) (adamantan-1-yl)(1-pentyl-1H-indol-3-yl)-methanone;
(136) (2-iodo-5-nitrophenyl)-[1–(1-methylpiperidin-2-ylmethyl)– 1H-indol-3-yl]-methanone;
(137) (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclo-propyl)methanone;
(138) [1–(5-fluoropentyl-1H-indol-3-yl)](2,2,3,3-tetramethylcyclo-propyl)methanone;
(139) [1–(2-morpholinoethyl)–1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone;
(140) 1-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-indol-3-yl-(2,2,3,3-tetramethylcyclopropyl)methanone;
(141) 1-pentyl-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indole-3-carboxamide;
(142) 1-pentyl-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indazole-3-carboxamide;
(143) 1–(5-fluoropentyl)–N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indole-3-carboxamide;
(144) [1–(5-chloropentyl)–1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone;
(145) (1-isopentyl-1H-indol-3-yl)(naphthalen-1-yl)methanone;
(146) 1–(5-fluoropentyl-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indazole-3-carboxamide;
(147) (1-pentyl-1H-indol-3-yl)(4-propyl-1-naphthalenyl)-methanone;
(148) [1–(5-chloropentyl)–1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone;
(149) (4-methyl-naphthalen-1-yl)[1–(pent-4-en-1-yl)–1H-indol-3-yl]methanone;
(150) (2-methoxy-1-naphthalenyl)(1-pentyl-1H-indol-3-yl)methanone;
(151) (3-methoxy-phenyl)(1-pentyl-1H-indol-3-yl)methanone;
(152) [1–(5-fluoropentyl)–1H-indol-3-yl](4-ethyl-1-naphthalenyl)- methanone;
(153) quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate;
(154) quinolin-8-yl 1–(5-fluoropentyl-1H-indole-3-carboxylate;
(155) 1–(cyclohexylmethyl)–8-quinolinyl-ester-1H-indole-3-carboxylic acid;
(156) N–(1-amino-3-methyl-1-oxobutan-2-yl)–1-pentyl-1H-indazole-3-carboxamide;
(157) 1–(5-fluoropentyl)–N–(naphthalene-1-yl)–1H-indole-3-carboxamide;
(158) N–(1-amino-3-methyl-1-oxobutan-2-yl)–1–(4-fluorobenzyl)–1H-indazole-3-carboxamide;
(159) N–(1-amino-3,3-dimethyl-1-oxobutan-2-yl)–1–(4-fluorobenzyl)–1H-indazole-3-carboxamide;
(160) N–(1-amino-3,3-dimethyl-1-oxobutan-2-yl)–1-pentyl-1H-indole-3-carboxamide;
(161) 2-iodophenyl)(1-pentyl-1H-indol-3-yl)methanone;
(162) [5–(2-methylphenyl)–1-pentyl-1H-pyrrol-3-yl]-1-naphthalenyl-methanone;
(163) 1-pentyl-N–(naphthalene-1-yl)–1H-indole-3-carboxamide;
(164) 1–(5-chloropentyl)–1H-indol-3-yl](4-methyl-1-naphthalenyl)-methanone;
(165) (4-methyl-naphthalen-1-yl)[2-methyl-1–(pent-4-en-1-yl)– 1H-indol-3-yl)]methanone;
(166) [1–(5-fluoropentyl)–1H-indol-3-yl](o-tolyl)methanone;
(167) (2-ethylphenyl)(1–(5-fluoropentyl)–1H-indol-3-yl)methanone;
(168) [1–(5-chloropentyl)–1H-indol-3-yl](naphthalen-1-yl)methanone;
(169) [1–(5-bromopentyl)–1H-indol-3-yl](naphthalen-1-yl)methanone;
(170) (1–(5-fluoropentyl)–1H-indazol-3-yl)(naphthalene-1-yl)methanone;
(171) 1-[(1-methyl-2-piperidinyl)methyl]-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone;
(172) (1–(1-methylazepan-2-yl)–1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone;
(173) 4-hydroxy-3,3,4-trimethyl-1–(1-pentyl-1H-indol-3-yl)pentan-1-one;
(174) [1–(4-fluoropentyl)–1H-indol-3-yl]-1-naphthenyl-methanone;
(175) 2–(2-iodophenyl)–1–(1-pentyl-1H-indol-3-yl)ethanone;
(176) (1-hexyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone;
(177) (2,2,3,3-tetramethylcyclopropyl)[1–(4,4,4-trifluorobutyl)– 1H-indol-3-yl]methanone;
(178) 7-methoxy-1–(2-morpholinoethyl)–N–((1S,4R)–1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl)–1H-indole-3-carboxamide;
(179) (4-fluorobenzyl)–1H-indole-3-quinolin-8-yl
Carboxylate;
(180) 1–(4-fluorobenzyl)–1H-indole-3-naphthalen-1-yl
Carboxylate;
(181) N–(1-amino-3,3-dimethyl-1-oxobutan-2-yl)–1-pentyl-1H-indazole-3-carboxamide;
(182) N–(1-amino-3,3-dimethyl-1-oxobutan-2-yl)–1–(5-fluoropentyl)–1H-indole-3-carboxamide;
(183) (1–(4-fluoropentyl)–1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone;
(184) 1-naphthalenyl(1-pentyl-1H-indazol-3-yl)methanone;
(185) N-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide;
(186) N–(1-amino-3-methyl-1-oxobutan-2-yl)–1–(cyclohexylmethyl)–1H-indazole-3-carboxamide;
(187) naphthalene-1-yl(9-pentyl-9H-carbazol-3-yl)methanone;
(188) naphthalene-1-yl 1–(5-fluoropentyl)–1H-indole-3-carboxylate;
(189) methyl 3-methyl-2–(1-pentyl-1H-indazole-3-carboxamido;
(190) methyl 2–(1–5-fluoropentyl)–1H-indazole-3-caboxamido) methylbutanoate;
(191) N-benzyl-1-pentyl-1H-indole-3-carboxamide;
(192) N-benzyl-1–(5-fluoropentyl)–1H-indole-3-carboxamide;
(193) methyl 2–(1–(4-fluorobenzyl)–1H-indazole-3-carboxamido)–3-methylbutanoate;
(194) quinolin-8-yl 1-pentyl-1H-indazole-3-carboxylate;
(195) quinolin-8-yl 1–(5-fluoropentyl)–1H-indazole-3-carboxylate;
(196) naphthalene-2-yl 1–(2-fluorophenyl)–1H-indazole-3-carboxylate;
(197) N–(1-amino-3,3-dimethyl-1-oxobutan-2-yl)–1–(cyclohexylmethyl)–1H-indazole-3-carboxamide;
(198) (1–(4-flourobenzyl)–1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone;
(199) N–(1-amino-1-oxo—3-phenylpropan-2-yl)–1–(5-fluoropentyl)–1H-indole-3-carboxamide;
(200) N–(1-amino-1-oxo—3-phenylpropan-2-yl)–1–(5-fluoropentyl)–1H-indazole-3-carboxamide;
(201) methyl (1–(cyclohexylmethyl)–1H-indazole-3-carbonyl-L-valinate;
(202) N-[(1–(cyclohexylmethyl)–1H-indazole-3yl)carbonyl]- 3-methyl-L-valine, methyl ester;
(203) methyl 2–(1–(cyclohexylmethyl)–1H-indole-3-carboxamido)–3,3-dimethylbutanoate;
(204) (1–(5-fluoropentyl)–1H-benzo[d]imidazole-2-yl)(naphthalene-1-yl)methanone;
(205) (1–(4-fluorobenzyl)–1H-indol-3-yl)(napthalen-1-yl)methanone;
(206) methyl 2–(1–(4-fluorobenzyl)–1H-indazole-3-carboxamido)–3,3-dimethylbutanoate;
(207) quinolin-8-yl1–(4-fluorobenzyl)–1H-indazole-3-carboxylate;
(208) N–(adamantan-1-yl)–1–(4-fluorobenzyl)–1H-indazole-3-carboxamide;
(209) N–(1-amino-3-methyl-1-oxobutan-2-yl)–1–(5-fluoropentyl)–1H-indole-3-carboxamide;
(210) 2-[(1S,3R)–3-hydroxycyclohexyl]-5–(2-methylheptyl-2-yl)phenol;
(211) 3-hydroxy-2[3-methyl-6–(1-methylethyenyl)–2-cyclohexen-1-yl]-5-pentyl-2,5-cyclohexadiene-1,4-dione;
(212) 4-[4–(1,1-dimethylheptyl)–2,6-dimethoxyphenyl]-6,6-dimethyl-bicyclo[3.1.1]hept-2-ene-2-methanol;
(213) 1-naphthalenyl[4–(pentylox)–1-naphthalenyl]-methanone;
(214) 3–(2–(hydroxymethyl)–2,3-dihydro-1H-inden-4-yloxy)phenyl 4,4,4-trifluorobutane-1-sulfonate;
(215) N–(benzo[1,3]dioxol-5-ylmethyl)–7-methoxy-2-oxo-8-pentyloxy-1,2-dihydroquinoline-3-carboxamide;
(216) N-[3–(2-methoxyethyl)–4,5-dimethylthiazol-2-ylidene]-2,2,3,3-tetramethylcyclopropane-carboxamide;
(217) 5-chloro-3-ethyl-N-[4–(piperidin-1-yl)phenethyl)–1H-indole-2-carboximide;
(218) N-[4–(dimethylamino)phenethyl]-3-ethyl-5-fluoro-1H-indole-2-carboximide;
(219) N–(1-benzylpyrrolidin-3-yl)–5-chloro-3-ethyl-1H-indole-2-carboxamide;
(220) [5–(2-fluorophenyl)–1-pentyl-1H-pyrrol-3-yl](naphthalene-1-yl)methanone;
(221) (3’-(aminocarbonyl)[1,1’-biphenyl]-3-yl)-cyclohexyl-carbamate;
(222) 5–(biphenyl-4-ylmethyl)–N,N-dimethyl-1H-tetrazole-1-carboxamide;
(223) 6-methyl-2–(p-tolylamino)–4H-benzo[d][1,3]oxazin-4-one;
(224) [1,1'-biphenyl]-3-yl-carbamic acid, cyclohexyl ester;
(225) 4-hydroxy-N–(4-hydroxyphenethyl)–3–(pentylamino)- benzamide; and
(226) 3’-carbamoyl-6-hydroxy-[1,1’-biphenyl]-3-ylcyclohexylcarbamate;
Subsection 1201.1(d) is amended to read as follows:
(d) Depressants: Unless specifically excepted or unless listed in another schedule, any material, compound, or mixture, or preparation that contains any quantity of the following substances having a depressant effect on the central nervous system including its salts, isomers, and salts of isomers, whenever the existence of the salts, isomers, and salts of isomers is possible, within the specific chemical designation:
(1) Cyclobarbital; Hexemal; Cyclobarbitone;
(2) Etaqualone; Athinazone; Ethinazone; 3-(2-ethylphenyl)-2-
methylquinazolin-4-one;
(3) Gamma-Hydroxybutyric Acid [other names include GHB; gamma-hydroxybutyrate; 4-hyrdroxybutyrate; 4-hydroxybutanoic acid; socium oxybate; sodium xybutyrate];
(4) Mecloqualone; and
(5) Methaqualone;
Subsection 1201.1(e) is amended to read as follows:
(e) Stimulants: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers:
(1) Alpha-ethyltryptamine;
(2) Alpha-methyltryptamine;
(3) Aminorex;
(4) Brolamfetamine, bromo-DMA, 2,5-Dimethoxy-4-bromoamphetamine, Dimethoxybromoamphetamine (DOB);
(5) 1,4-dibenzylpiperazine;
(6) 1–(4-bromo-2,5-dimethoxybenzyl)-piperazine;
(7) 1–(4-fluorophenyl)-piperazine;
(8) 1–(2-methoxyphenyl)-piperazine;
(9) 1–(4-chlorophenyl)-piperazine;
(10) 1–(4-methoxyphenyl)-piperazine;
(11) 1–(3-methylbenzyl)piperazine;
(12) 1-benzyl-4-methylpiperazine;
(13) 8-methyl-8-azabicyclo[3.2.1]octan-3-yl 4-fluorobenzoate;
(14) methyl 3–(4-fluorophenyl)–8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate;
(15) Cathinone; Any compound (not being bupropion) structurally derived from 2-amino-1-phenyl-1-propanone by modification in any of the following ways:
(A) By substitution in the phenyl ring to any extent with alkyl, alkoxy, alkylenedioxy, haloalkyl or halide substituents, whether or not further substituted in the phenyl ring by one or more other univalent substituents;
(B) By substitution at the 3-position with an alkyl substituent; or
(C) By substitution at the nitrogen atom with alkyl or dialkyl groups, or by inclusion of the nitrogen atom in a cyclic structure;
(16) 2-diphenylmethylpyrrolidine, including 2-Benzylhydrylpyrrolidin, (S)-(-)-2-(diphenylmethyl)pyrrolidine, (S)-2-diphenylmethylpyrrolidine; (2S)-2-Benzylhydrylpyrrolidine; (2S) diphenylmethylpyrrolidine;
(17) Fenethylline;
(18) Mephedrone (4-methyl-N-methylcathinone), BZ-6378, 4-methylephedrone;
(19) Methcathinone, including 4-MEC 4-methyl-N-ethylcathinone, 4-methylethcathinone, para-methyl-N-ethylcathinone, para-methylethcathinone, 4-methyl-ethylcathinone;
(20) Methylenedioxypyrovalerone (MDPV);
(21) Methylone;
(22) N-Benzylpiperazine, (BZP) benzylpiperazine, N-benzylpiperazine;
(23) N-ethylamphetamine;
(24) N-Hydroxy-3, 4-methylenedioxyamphetamine;
(25) N, N-Dimethylamphetamine;
(26) 4-methyl-N-ethylcathinone (“4-MEC”);
(27) 4-methyl-alpha-pyrrolidinopropiophenone (“4-MePPP”);
(28) Alpha-pyrrolidinopentiophenone (“α-PVP”), (a-PVP, alpha-PVP), a-Pyrrolidinopentiophenone, 1-phenyl-2-(1 -pyrrolidinyl)-1-pentanone, alpha-pyrrolidinovalerophenone, a-pyrrolidinovalerophenone;
(29) 1-(1, 3-benzodioxol-5-yl)-2-(methylamino)butan-1-one (“butylone”);
(30) 2-(methylamino)-1-phenylpentan-1-one (“pentedrone”);
(31) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one (“pentylone”);
(32) 4-fluoro-N-methylcathinone (“4-FMC”), including 4-ethylmethcathinone, 4-ethyl-methcathinone, Flephedrone, 4-fluoromethcathinone;
(33) 3-fluoro-N-methylcathinone (“3-FMC”), 3-fluoromethcathinone;
(34) 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one (“naphyrone”);
(35) Alpha-pyrrolidinobutiophenone (“α-PBP”) (a-PBP, alpha-PBP) alpha-Pyrrolidinobutiophenone, a-Pyrrolidinobutiophenone, (RS)1-phenyl-2-(1-pyrrolidinyl)-1-pentanone;
(36) 2-DPMP, including desoxypipradrol, diphenylprolinol, 2-
Diphenylmethylpiperidine, 2-benzhydrylpiperidine;
(37) 2-FMC, 2-fluoromethcathinone;
(38) 3,4-DMMC, 3,4-dimethylmethcathinone;
(39) 4-MBC, Benzedrone, (±)-1-(4-methylphenyl)-2-(benzylamino)propan-1-one, 4-methyl-N-benzylcathinone,N-benzyl-4-methylcathinone, 1-(4 methylphenyl)-2-benzyla-minopropan-1-one;
(40) 4-MeMABP, 4-methylbuphedrone, (2-Methylamino-1-(4-methylphenyl)butan-1-one), 2-methylamino-1-(4-methylphenyl)butan-1-one;
(41) a-PPP, alpha-PPP, alpha-pyrrolidinopropiophenone, a-pyrrolidinopropiophenone;
(42) Buphedrone, a-methylamino-butyrophenone, 2-(methylamino)-1-phenylbutan-1-one, alpha-methylamino-butyrophenone;
(43) Butylone, bk-MBDB, beta-Keto-N-methylbenzodioxolylpropylamine, beta-Keto-N-methyl-3,4-benzodioxyolybutanamine;
(44) D2PM, diphenyl-2-pyrrolidinyl-methanol;
(45) Dimethocaine, (3-diethylamino-2,2-dimethylpropyl)-4-aminobenzoate;
(46) DMBDB, bk-DMBDB,dibutylone, 1-(Benzo[d][1,3]dioxol-5-yl)-2-(dimethylamino)butan-1-Dibutylone) one;
(47) DMEC, dimethylethcathinone;
(48) DMMC, dimethylmethcathinone;
(49) Ephedrone (sometimes used as another name for methcathinone)
2-(methylamino)-1-phenylpropan-1-one; OR 2-methylamino-1-phenylpropan-1-one;
(50) Ethcathinone, 2-ethylamino-1-phenyl-propan-1-one;
(51) Ethylethcathinone;
(52) Ethylmethcathinone;
(53) Ethylone 3,4-methylenedioxy-N-ethylcathinone; OR 3,4-methylenedioxyethylcathinone; OR 3,4-methylenedioxy-ethylcathinone; OR 3,4-methylenedioxyethcathinone;
(54) Eutylone beta-Keto-Ethylbenziodioxolylbutanamine;
(55) Fluorococaine;
(56) Fluoroethcathinone;
(57) Fluoroisocathinone;
(58) Fluoromethcathinone;
(59) HMMC 3-methoxymethcathinone;
(60) Isopentedrone;
(61) MaPPP, 4-MePPP, MPPP 4-methyl-alpha-pyrrolidinopropiophenone; OR 4-methyl-a-pyrrolidinopropiophenone; OR methylpyrrolidinopropiophenone; OR Methyl-pyrrolindinopropiophenone;
(62) MBP Methylbuphedrone;
(63) MBZP 1-methyl-4-benzylpiperazine;
(64) MDAI methylenedioxy-aminoindane; OR 5,6-methylenedioxy-2-aminoindane;
(65) MDAT 6,7-methylenedioxy-2-aminotetralin;
(66) MDDMA Dimethylone;
(67) MDMC Methylenedioxymethcathinone;
(68) MDPBP 3,4-methylenedioxy-alpha-pyrrolidinobutiophenone; OR 3,4-methylenedioxy-a-pyrrolidinobutiophenone;
(69) MDPPP 3,4-methylenedioxy-a-pyrrolidinopropiophenone; OR (RS)-1-(3,4-methylenedioxyphenyl)-2-(1-pyrrolidinyl)-1-propanone; OR 3,4-methylenedioxy-alpha-pyrrolidinopropiophenone;
(70) MDPV, MDPK 3,4-methylenedioxypyrovalerone; OR methylenedioxypyrovalerone;
(71) MEC Methylethcathinone;
(72) Mephedrone, 4-MMC 4-methylmethcathinone; OR 4-methylephedrone; OR (RS)-2-methylamino-1-(4-methylphenyl)propan-1-one;
(73) Metamfepramone, N,N-DMMC N,N-dimethylcathinone;
(74) Methedrone, Bk-PMMA, PMMC para-methoxymethcathinone; OR 4-methoxymethcathinone; OR methoxyphedrine; OR (RS)-1-(4-methoxyphenyl)-2-(methylamino)propan-1-one;
(75) Methylmethcathinone;
(76) Methylone, bk-MDMA, MDMC 3,4-methylenedioxy-N-methylcathinone; OR 3,4-methylenedioxymethcathinone; OR 3,4-methylenedioxymethylcathinone;
(77) MOMC Methoxymethcathinone;
(78) MOPPP 4-methoxy-alpha-pyrrolidinopropiophenone; OR 4-methoxy-a-pyrrolidinopropiophenone;
(79) MPBP 4-methyl-alpha-pyrrolidinobutyrophenone; OR 4-methyl-a-pyrrolidinobutryophenone; OR 4-methyl-alpha-pyrrolidinobutiophenone; OR 4-methyl-a-pyrrolidinobutiophenone;
(80) NRG-1, Naphyrone naphthylpyrovalerone;
(81) NRG-2;
(82) Pentedrone a-methylamino-Valerophenone; OR 2-(methylamino)-1-phenyl-1-pentanone; OR 2-methylamino-1-phenyl-1-pentanone;
(83) Pentylone beta-Keto-N-methylbenzodioxolylpentanamine; OR beta-keto-ethylbenzodioxolylpentanamine;
(84) 1-(2-Fluorophenyl)propan-2-amine, (2-FA);
(85) N-Methyl-1-(benzofuran-2-yl)propan-2- amine, (2-MAPB);
(86) 1-(3-Fluorophenyl)propan-2-amine, (3-FA), (RS)-1-(3-Fluorophenyl)propan-2-amine;
(87) (RS)-1-(3-fluorophenyl)-N-methylpropan-2-amine, (3-FMA);
(88) 1-(4-Chlorophenyl)propan-2-amine, para-Chloroamphetamine (PCA), 4-chloroamphetamine (4-CA);
(89) Levmetamfetamine or (-)-Methamphetamine; L-Methylamphetamine or (-)-Deoxyephedrine or R(-)-N-Methylamphetamine;
(90) 1–(3-fluorophenyl)–2–(methylamino)–1-propanone;
(91) 1–(4-fluorophenyl)–2–(methylamino)–1-propanone;
(92) 1–(4-methoxyphenyl)–2–(methylamino)–1-propanone;
(93) 2–(ethylamino)–1–(4-methoxyphenyl)–1-propanone;
(94) 1–(2-naphthalenyl)–2–(1-pyrrolidinyl)–1-pentanone;
(95) 1–(1,3-benzodioxol-5-yl)–2–(methylamino)–1-butanone;
(96) 1–(1,3-benzodioxol-5-yl)–2–(methylamino)–1-pentanone;
(97) 2–(ethylamino)–1-phenyl-1-propanone;
(98) 1-phenyl-2–(1-pyrrolidinyl)–1-propanone;
(99) 1–(4-methylphenyl)–2–(1-pyrrolidinyl)–1-propanone;
(100) 1–(4-methoxyphenyl)–2–(1-pyrrolidinyl)–1-propanone;
(101) 1–(1,3-benzodioxol-5-yl)–2–(1-pyrrolidinyl)–1-propanone;
(102) 1-phenyl-2–(1-pyrrolidinyl)–1-pentanone;
(103) 2-amino-1–(4-fluoro)–1-propanone;
(104) 2–(ethylamino)–1–(4-ethylphenyl)–1-propanone;
(105) 2–(dimethylamino)–1-phenyl-1-propanone;
(106) 1–(1,3-benzodioxol-5-yl)–2–(1-pyrrolidinyl)–1-butanone;
(107) 1–(methylphenyl)–2–(1-pyrrolidinyl)–1-hexanone;
(108) 1–(methylphenyl)–2–(1-pyrrolidinyl)–1-hexanone;
(109) 2–(methylamino)–1-phenyl-1-butanone;
(110) 2–(methylamino)–1-p-tolyl-1-butanone;
(111) 1–(4-methylphenyl)–2–(1-pyrrolidinyl)–1-butanone;
(112) 1–(3,4-dimethylphenyl)–2–(methylamino)–1-propanone;
(113) 1-phenyl-2–(1-pyrrolidinyl)–1-butanone;
(114) 1–(1,3-benzodioxol-5-yl)–2–(dimethylamino)–1-propanone;
(115) 1–(4-methylphenyl)–2–(benzylamino)–1-propanone;
(116) 1–(1-naphthy)–2–(1-pyrrolidinyl)–1-pentanone;
(117) 1–(1,3-benzodioxol-5-yl)–2–(benzylamino)–1-propanone;
(118) 1–(1,3-benzodioxol-5-yl)–2–(benzylamino)–1-butanone;
(119) 1–(1,3-benzodioxol)–2-[hydroxy(methyl)-amino]-1- propanone;
(120) 1–(1,3-benzodioxol-5-yl)–2–(dimethylamino)–1-butanone;
(121) 2–(ethyl(methyl)amino)–1-phenyl-butanone;
(122) 2–(ethyl(methyl)amino-1-phenyl-1-propanone;
(123) 2–(methylamino)–1-m-tolyl-1-propanone;
(124) 2–(pyrrolidin-1-yl)–1–(thiophen-2-yl)–1-pentanone;
(125) 1–(4-fluorophenyl)–2–(methylamino)–1-butanone;
(126) 1–(4-methoxyphenyl)–2–(pyrrolidin-1-yl)–1-butanone;
(127) 1–(4-ethylphenyl)–2–(pyrrolidin-1-yl)–1-butanone;
(128) 1–(4-methoxy-3-methylphenyl)–2–(methylamino)–1- propanone;
(129) 2–(ethylamino)–1–(3-methylphenyl)–1-propanone;
(130) 2-amino-(1H-indol-5-yl)propan-1-one;
(131) 1-phenyl-2–(piperidin-1-yl)butan-1-one;
(132) 2-methylamino-1–(2,4,5-trimethylphenyl)-propan-1-one);
(133) 1–(4-fluorophenyl)–2–(pyrrolidin-1-yl)pentan-1-one;
(134) 1–(benzo[d][1,3]dioxol-5-yl)–2–(dimethylamino)pentan-1-;
(135) 1–(2-fluorophenyl)–N-methyl-propan-2-amine;
(136) 1–(2-fluorophenyl)-propan-2-amine;
(137) 1–(3-fluorophenyl)- propan-2-amine;
(138) 1–(3-fluorophenyl)–N-methyl-propan-2-amine;
(139) N-ethyl-N-methyl-1-phenylpropan-2-amine;
(140) 1–(benzofuran-4-yl)propan-2-amine;
(141) 1–(2,3-dihydrobenzofuran-5-yl)proan-2-amine;
(142) 1–(2,3-dihydrobenzofuran-6-yl)proan-2-amine;
(143) N,N-dimethyl-1-phenylpropan-2-amine;
(144) 5,6,7,8-tetrahydrobenzo[1,3]-benzodioxol-7-amine;
(145) a-methyl-4–(methylthio)-benzene-ethanamine;
(146) 1–(4-chlorophenyl)-propan-2-amine;
(147) 1–(2,4,6-trimethoxyphenyl)-propan-2-amine;
(148) 1–(2,4,5-trimethoxyphenyl)-propan-2-amine;
(149) 1–(2,5-dimethylphenyl)-propan-2-amine;
(150) 1–(3,4-dimethylphenyl)-propan-2-amine;
(151) N–(1-phenylpropan-2-yl)propan-1-amine;
(152) 4–(2-aminopropyl)phenol;
(153) 3,4-methylenedioxy-N,N-dimethyl-amphetamine;
(154) N-ethyl-1–(4-methoxyphenyl)propan-2-amine;
(155) 6,7-dihydro-5H-inden[5,6-d][1,3]dioxol-6-amine;
(156) 5-methoxy-6-methyl-2,3-dihydro-1H-inden-2-amine;
(157) N-methyl-6,7-dihydro-5H-cyclopenta[1,3]-benzodioxol-6- amine;
(158) N-methyl-2,3-dihydro-1H-inden-2-amine;
(159) 2-[4–(2-fluoroethylthio)–2,5- dimethoxyphenyl]ethanamine;
(160) 8-bromo-2,3,6,7-tetrahydro-benzo[1,2-b;4,5-b’]difuran-4-ethanamine;
(161) 4-iodo-2,5-dimethoxy-N-[(2-methoxyphenyl)-methyl-benzene-ethamine;
(162) 2–(4-chloro-2,5-dimethoxyphenyl)–N–(2-methoxybenzyl)-ethanamine;
(163) 2–(2,5-dimethoxy-3,4-dimethylphenyl)-ethanamine;
(164) 2–(4-ethyl-2,5-dimethoxyphenyl)–N–(2-methoxybenzyl)-ethanamine;
(165) 2–(2,5-dimethoxy-3,4-dimethylphenyl)–N–(2- methoxybenzyl)-ethanamine;
(166) 2–(2,5-dimethoxyphenyl)–N–(2-methoxybenzyl)-ethanamine;
(167) 2–(2,5-dimethoxyphenyl-4-nitro)–N-[(2-methoxyphenyl)methyl]-ethanamine;
(168) 1–(4-iodo-2,5-dimethoxyphenyl)propan-2-amine;
(169) 1–(4-chloro-2,5-dimethoxyphenyl)propan-2-amine;
(170) 1–(4-bromo-2,3,6,7-terahydrofuro[2,3-f]benzofuran-8-yl)propan-2-amine;
(171) (2,5-dimethoxyphenyl)-propan-2-amine;
(172) 1-[4–(ethylthio)–2,5-dimethoxyphenyl)propan-2-amine;
(173) 1–(4-ethoxy-2,5-dimethoxyphenyl)propan-2-amine;
(174) 1-[2,5-dimethoxy-4–(propylthio)phenyl]propan-2-amine;
(175) 1–(4-ethyl-2,5-dimethoxyphenyl)propan-2-amine;
(176) N-benzyl-2-phenylethanamine;
(177) N,N-dimethyl-2-phenylethanamine;
(178) 6-chloro-aminotetralin;
(179) 2-phenethylamine;
(180) 2-phenyl-propan-1-amine;
(181) 1-methylamino-1–(3,4-methylendioxy-phenyl)propane;
(182) N-methyl-3-phenylbicyclo[2.2.1]heptan-2-amine;
(183) 1–(2-methoxyphenyl)–N-methylpropan-2-amine;
(184) 2–(4–(allyloxy)–3,5-dimethoxyphenyl)ethanamine;
(185) 4-methylhexan-2-amine;
(186) 4-methyl-5-phenyl-2-amino-oxazoline;
(187) (3-dimethylamino-2,2-dimethylpropyl)–4-aminobenzoate;
(188) 1–(4-fluorophenyl)–2–(methylamino)-propan-1-ol;
(189) 4-methyl-5-p-tolyl-4,5-dihydrooxazol-2-amine;
(190) 1-phenyl-2–(pyrrolidin-1-yl)propan-1-ol;
(191) 1–(3-methoxyphenyl)–N-propylcyclohexan-amine;
(192) 2–(ethylamino)–2–(3-methoxyphenyl)cyclohexanone;
(193) 1-phenylcyclohexan-amine;
(194) 1-[1–(benzothiophen-2-yl)cyclohexyl]piperidine;
(195) 1–(1-p-tolylcyclohexyl)-piperidine;
(196) 1–(4-methoxyphenyl)–N-propylcyclohexan-amine;
(197) 1-[1–(4-methoxyphenyl)cyclohexyl]-piperidine;
(198) 1-[1–(3-methoxyphenyl)cyclohexyl]-piperidine;
(199) 1-phenyl-N-propylcyclohexanamine;
(200) N–(2-methoxyethyl)–1-phenylcyclohexan-amine;
(201) N–(2-ethoxyethyl)–1-phenylcyclohexan-amine;
(202) N–(3-methoxypropyl)–1-phenylcyclohexan-amine;
(203) 3-[1–(piperidin-1-yl)cyclohexyl]-phenol;
(204) 2–(methoxyphenyl)–2–(methylamino)cyclohexanone;
(205) N-ethyl-1–(thiophen-2-yl)cyclohexanamine;
(206) (2–(2-chlorophenyl)–2–(ethylamino)-cyclohexanone);
(207) 2–(diphenylmethyl)-piperidine;
(208) 2-benzhydrylpyrrolidine;
(209) a,a-diphenyl-(pyrrolidin-2-yl)methanol;
(210) methyl 2–(3,4-dichlorophenyl)–2–(piperdin-2-yl)acetate;
(211) methyl 2–(3-chlorophenyl)–2–(piperidin-2-yl)acetate;
(212) methyl 2–(piperidin-2-yl)–2-p-tolylacetate; and
(213) ethyl 2-phenyl-2–(piperidin-2-yl)acetate;
Subsection 1201.1(f)(2) is amended to read as follows:
(2) Unclassified Synthetic Cannabinoids:
(A) AM-087 (6aR,10aR)-3-(2-methyl-6-bromohex-2-yl)- 6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;
(B) AM-356 (methanandamide); (5Z,8Z,11Z,14Z)-N-[(1R)-2-hydroxy-1-methylethyl] icosa-5,8,11,14-tetraenamide; or arachidonyl-1'- hydroxy-2'-propylamide;
(C) (5Z,8Z,11Z,14Z)-N-[(1R)-2-hydroxy-1-methylethyl] icosa-5,8,11,14-tetraenamide; or arachidonyl-1'-hydroxy-2'-propylamide;
(D) AM-411(6aR,10aR)-3-(1-adamantyl)-6,6,9-trimethyl- 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;
(E) AM-855(4aR,12bR)-8-hexyl-2,5,5-trimethyl-1,4,4a,8, 9,10,11,12b-octahydronaphtho[3,2-c]isochromen-12-ol;
(F) AM-905(6aR,9R,10aR)-3-[(E)-hept-1-enyl]-9-
(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-1-ol;
(G) AM-906(6aR,9R,10aR)-3-[(Z)-hept-1-enyl]-9-
(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-1-ol;
(H) AM-2389(6aR,9R,10aR)-3-(1-hexyl-cyclobut-1-yl)-
6a,7,8,9,10,10a-hexahydro-6,6-dimethyl-6H-dibenzo[b,d]pyran-1,9 diol;
(I) BAY38-7271(-)-(R)-3-(2-Hydroxymethylindanyl-4-oxy) phenyl-4,4,4-trifluorobutyl-1-sulfonate;
(J) CP 50,556-1 (Levonantradol);
(K) 9-hydroxy-6-methyl-3-[5-phenylpentan-2-yl]oxy-5,6, 6a,7,8,9,10,10a-octahydrophenanthridin-1-yl]acetate; or [(6S,6aR,9R,10aR)-9-hydroxy-6-methyl-3-[(2R)-5- ph enylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-;
(L) octahydrophenanthridin-1-yl] acetate; or [9-hydroxy-6-methyl-3-[5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10, 10a-octahydrophenanthridin-1-yl]acetate;
(M) HU-210(6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-
3-;
(N) (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c] chromen-1-ol; or [(6aR,10aR)-9-(hydroxymethyl) -6,6-dimethyl-3- (2-methyloctan-2-yl)-6a,7,10,10a- tetrahydrobenzo[c]chromen-1-ol; or 1,1-Dimethylheptyl- 11-hydroxytetrahydrocannabinol;
(O) HU-211 (Dexanabinol);
(P) (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3- (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol; or (6aS,10aS)-9-(hydroxymethyl) -6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;
(Q) HU-2433-dimethylheptyl-11- hydroxyhexahydrocannabinol;
(R) HU-308[(91R,2R,5R)-2-[2,6-dimethoxy-4- (2-methyloctan-2-yl)phenyl]-7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl]methanol;
(S) HU-3313-hydroxy-2-[(1R,6R)-3-methyl-6- (1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-2,5-cyclohexadiene-1,4-dione;
(T) JTE-907N-(benzol[1,3]dioxol-5-ylmethyl) -7-methoxy-2-oxo-8-pentyloxy-1,2-dihydroquinoline-3-carboxamide;
(U) JWH-051((6aR,10aR)-6,6-dimethyl-3- (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-9-yl)methanol;
(V) JWH-057(6aR,10aR)-3-(1,1-dimethylheptyl) -6a,7,10,10a-tetrahydro-6,6,9-trimethyl-6H-Dibenzo[b,d]pyran;
(W) JWH-133(6aR,10aR)-3-(1,1-Dimethylbutyl) -6a,7,10,10a-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran;
(X) JWH-359 (6aR,10aR)- 1-methoxy- 6,6,9-trimethyl- 3-[(2R)-1,1,2-trimethylbutyl]- 6a,7,10,10a-tetrahydrobenzo[c]chromene;
(Y) URB-597[3-(3-carbamoylphenyl)phenyl] -N-cyclohexylcarbamate;
(Z) URB-602 [1,1'-Biphenyl]-3-yl-carbamic acid, cyclohexyl ester; or cyclohexyl [1,1'-biphenyl]-3-ylcarbamate;
(AA) URB-7546-methyl-2-[(4-methylphenyl)amino] -4H-3,1-benzoxazin-4-one;
(BB) URB-937 3'-carbamoyl-6-hydroxy-[1,1'-biphenyl]-3-yl cyclohexylcarbamate;
(CC) WIN 55,212-2(R)-(+)-[2,3-dihydro-5-methyl-3- (4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-napthalenylmethanone; or [2,3-Dihydro-5-methyl- 3-(4-morpholinylmethyl)pyrrolo[(1,2,3-de)-1,4-benzoxazin-6-yl]-1-napthalenylmethanone;
(DD) AM-2201 (1-(5-fluoropentyl)-3-(1-naphthoyl)indole);
(EE) AM-694 (1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole);
(FF) Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (“PB-22”; QUPIC);
(GG) Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (“5-fluoro-PB-22”; 5F-PB-22);
(HH) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (“AB-FUBINACA”);
(II) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (“ADB-PINACA”);
(JJ) THJ-2201 [1-(5-fluoropentyl)-1H-indazol-3-1yl](naphthalen-1-yl)methanone;
(KK) (N-(1-amino-3-methyl-1- oxobutan-2-yl)-1-(cyclohexylmethyl)- 1H-indazole-3-carboxamide (“AB-CHMINACA”);
(LL) (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide) (“AB-PINACA“);
(MM) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(5-fluoropentyl)-1H-indazole-3-carboxamide, (5F-AB-PINACA);
(NN) N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide, (5F-ADBICA or 5F-ADB-PICA);
(OO) (S)-methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate, (5F-AMB or 5F-MMB-PINACA or 5F-AMB-PINACA); and
(PP) N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide, N-(1-Adamantyl)-1-(5-fluoropenty1)-1 H- indazole-3-carboxarnide, (5F-APINACA or 5F-AKB48);
Subsection 1201.1 is amended by adding two new paragraphs (g) and (h) to read as follows:
(g) Substituted tryptamines. This includes any compound, unless specifically excepted, specifically named in this schedule, or listed under a different schedule, structurally derived from 2-(1H-indol-3-yl) ethanamine (i.e., tryptamine) by mono- or di-substitution of the amine nitrogen with alkyl or alkenyl groups or by inclusion of the amino nitrogen atom in a cyclic structure regardless of whether the compound is further substituted at the alpha position with an alkyl group or further substituted on the indole ring to any extent with any alkyl, alkoxy, halo, hydroxyl, or acetoxy groups. Examples include the following:
(1) (4-AcO-DET) 3-(2-Diethylaminoethyl)-1H-indol-4-yl acetate (DET);
(2) (4-AcO-DMT, OAcetylpsilocin) 4-acetoxy-N,N-dimethyltryptamine;
(3) (4-AcO-DPT) 4-acetoxy-N,N-dipropyltryptamine;
(4) (4-HO-DiPT) 4-Hydroxy-di-isopropyl-tryptamine; OR 3-[2- (diisopropylamino)ethyl]-1H-indol-4-ol; OR 4-Hydroxy- N,N-diisopropyltryptamine;
(5) (4-HO-MET) 4-hydroxy-N-methyl-N-ethyltryptamine;
(6) (4-HO-MiPT) 3-(2-[Isopropyl(methyl)amino]ethyl)-1H-indol-4-ol;
(7) (4-HO-MPMI) (R)-3-(N-methylpyrrolidin-2-ylmethyl)-4-hydoxyindole;
(8) (4-HO-MPT) 3-{2-[methyl(propyl)amino]ethyl}-1H-indol-4-ol; OR 4- hydroxy-N-methyl-N-propyltryptamine;
(9) (4-MeO-MiPT) 4-methoxy-N-methyl-N-isopropyltryptamine; OR 3-[2 (Isopropylmethylamino)ethyl]-4-methoxyindole;
(10) 4-methyl-aET 4-Methyl-α-ethyltryptamine; OR 1-ethyl-2-(4-methyl-1H- indol-3-yl)-ethylamine;
(11) (5-MeO-AMT) 1-(5-methoxy-1H-indol-3-yl)propan-2-amine;
(12) (5-MeO-DALT) N,N-diallyl-5-methoxytryptamine; OR N-allyl-N-[2-(5- methoxy-1H-indol-3-yl)ethyl]prop-2-en-1-amine;
(13) (5-MeO-DET) N,N-Dethyl-5-Methoxytryptamine;
(14) (5-MeO-DPT) N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-propylpropan-1- amine;
(15) (5-MeO-MiPT, Moxy, Moxie) N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-methylpropan-2-amine;
(16) (5-MeO-MPMI) (R)-3-(N-methylpyrrolidin-2-ylmethyl)-5-methoxyindole;
(17) (DPT) N,N-Dipropyltryptamine; OR Dipropyltryptamine; OR 3-[2-(dipropylamino)ethyl]indole;
(18) (Methyltryptamine, NMT) N-methyltryptamine; OR 2-(1H-Indol-3-yl)-N-methylethanamine; and
(19) (MiPT) N-isopropyl-N-methyltryptamine;
(20) 2–(1H-indol-3-yl)–N-methyl-ethanamine;
(21) N–(2–(1H-indol-3-yl)ethyl-N-methylpropan-2-amine;
(22) N-[2–(1H-indol-3-yl)ethyl]-N-isopropylpropan-2-amine;
(23) N,N-dipropyl-1H-indole-3-ethanamine;
(24) 3-[2–(diethylamino)ethyl]-1H–4yl acetate;
(25) 3–(2-[isopropyl(methyl)amino]ethyl)–1H-indol-4-ol;
(26) 3-[2–(bis[1-methylethyl]amino)ethyl]-1H-indol-4-ol acetate;
(27) 3–(2-[isopropyl(methyl)amino]ethyl)–1H-indol-4-ol acetate;
(28) 3-[2–(dimethylamino)ethyl]-1H-indol-4-yl acetate;
(29) 4-hydroxy-N,N-diethyl-1H-indole-ethanamine;
(30) 4-methoxy-N,N-dimethyl-1H-indole-3-ethanamine;
(31) 3–(2–(diisopropylamino)ethyl)–1H-indol-4-ol;
(32) 3-[2–(ethyl[methyl]amino)ethyl]-1H-indol-4-yl acetate;
(33) 3–(2–(dipropylamino)ethyl)–1H-indol-4-ol;
(34) 3-[2–(dipropylamino)ethyl]-1H-indol-4-yl acetate;
(35) 4-acetoxy-N,N-di-2-propen-1-yl-1H-indole-3-ethanamine;
(36) 5-methoxy-N,N-di-2-propen-1-yl-1H-indole-3-ethanamine;
(37) 3–(2–(dimethylaminoethyl)–1H-indol-5-ol;
(38) 2–(5-methoxy-1H-indol-3-yl)–N,N-dimethylethanamine;
(39) N-[2–(5-methoxy-1H-indol-3-yl)ethyl]-N-methylpropyl;
(40) 1–(5-methoxy-1H-indol-3-yl)propan-2-amine;
(41) 3-[2–(dimethylamino)-ethyl]-1H-indol-5-yl acetate;
(42) N-[2–(5-methoxy-1H-indol-3-yl)ethyl]-N-propylpropan-1-amine;
(43) N,N-diethyl-2–(5-methoxy-1H-indol-3-yl)ethanamine; and
(44) N-ethyl-2–(5-methoxy-1H-indol-3-yl)–N-methyl-ethanamine;
(h) Unclassified novel psychoactive substances
(1) (2-AI, 2-aminoindane) 2,3-dihydro-1H-inden-2-amine;
(2) (2-FMA) 2-fluoromethamphetamine; OR (RS)-1-(2-fluorophenyl)-N-methylpropan-2-amine; N-Methyl-1-(3-fluorophenyl)propan-2- amine;
(3) (2-MeO-ketamine) methoxyketamine;
(4) (3-HO-PCE) 3-[1-(ethylamino) cyclohexyl]phenol;
(5) (3-HO-PCP) 3-hydroxyphencyclidine (3-MeO-PCE) 3-Methoxyeticyclidine;
(6) (3-MeO-PCP) 1-[1-(3-methoxyphenyl)cyclohexyl]-piperidine; OR 3-methoxyphencyclidine;
(7) (4-FMA) 4-fluoromethamphetamine; OR (RS)-1-(4-fluorophenyl)-N-methylpropan-2-amine; N-Methyl-1-(4-fluorophenyl)propan-2-amine;
(8) (4-MeO-PCP, methoxydine) 4-Methoxyphencyclidine; OR 1-[1-(4-methoxyphenyl)cyclohexyl]-piperidine;
(9) (5-IAI) 5-Iodo-2-aminoindane; OR 5-iodo-2,3-dihydro-1H-inden-2-amine;
(10) (5-ME) 5-methyl-ethylone;
(11) (BTCP) Benzothiophenylcyclohexylpiperidine;
(12) (DBP, DBZP) 1,4-Dibenzylpiperazine;
(13) (Ethyl-ketamine) 2-(2-chlorophenyl)-2-(ethylamino)cyclohexanone;
(14) (Fluoromethamphetamine);
(15) (Fluorophenylpiperazine; pFPP; 4-FPP; fluoperazine; flipiperazine) Para-fluorophenylpiperazine; OR 1-(4-fluorophenyl)piperazine;
(16) (Kratom) 7-hydroxymitragynine;
(17) (MCPP) 1-(3-Chlorophenyl)piperazine, OR Chlorophenylpiperazine, OR meta chlorophenylpiperazine; OR 1-(3-chlorophenyl)piperazine; OR 3-chlorophenylpiperazine;
(18) (Methiopropamine, MPA) 1-(thiophen-2-yl)-2-methylaminopropane; N-Methyl-1-(thiophen-2-yl)propan-2-amine;
(19) (Methoxetamine, MXE, 3 MeO-2-Oxo-PCE) (RS)2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone;
(20) (MPHP) Methyl-alpha-pyrrolidinohexiophenone; OR Methyl-pyrrolidino-hexanophenone;
(21) (O-desmethyltramadol, O-DT) 3-[2-(1-Amino-1-methylethyl)-1-hydroxycyclohexyl]phenol;
(22) (Phenazepam) 7-Bromo-5-(2-chlorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one;
(23) (pMeOPP, MeOPP) 1-(4-Methoxyphenyl) piperazine;
(24) (pTFMPP) 1-[4-(trifluoromethylphenyl)] piperazine;
(25) (TFMPP) 3-trifluoromethylphenylpiperazine; OR 1-[3-(trifluoromethyl)phenyl]piperazine; OR 1-(3-trifluoromethylphenyl) piperazine; OR 1-(3-trifluoromethylphenyl)piperazine; OR 1-(3-[trifluoromethylphenyl])piperazine.
(26) (±)-2,5-Dimethoxy-alpha-methylphenethylamine, (DMA);
(27) 6,6,9-Trimethyl-3-(3-methyl-2-octanyl)-7,8,9,10-tetrahydro-6H-benzo[c]chromen-1-ol, (DMHP), Dimethylheptylpyran;
(28) 3-(2-(Dimethylamino)ethyl)indole, (DMT);
(29) P-methoxy-alpha-methylphenethylamine, (PMA);
(30) Methylenedioxyamphetamine, 3,4-methylenedioxy-amphetamine, MDA, tenamfetamine (INN), Sally, Sass, Sass-a-frass;
(31) Tenocyclidine (TCP);
(32) N-(1-Amino-3-methyl-1-oxobutan-2-y\)- l -(5-fluoropenty1)-1H-indole-3-carboxamide, (5F-ABICA);
(33) [1-(2-morpholin-4-ylethyl)-1H-indol-3-yl]-(2,2,3,3-tetramethylcyclopropyl) methanone, (A-796,260);
(34) N-[(1S)-1-(Aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide, (AB-CHMINACA);
(35) (4-F-a-PVP) 1-(4-fluorophenyl)-2-(1-pyrrolidinyl)pentan-1-one;
(36) (4-MeBP) 1-(4-Methylphenyl)-2-methylaminobutan-1-one;
(37) (4-MeO-a-PVP) 1-(4-methoxyphenyl)-2-(1-pyrrolidinyl)pentan-1-one;
(38) (NEB) 1-phenyl-2-ethylaminobutan-1-one;
(39) (a-PHP) 1-phenyl-2-(1-pyrrolidinyl)hexan-1-one;
(40) (a-PHPP) 1-phenyl-2-(1-pyrrolidinyl)heptan-1-one;
(41) (a-PVT) 1-(thiophen-2-yl)-2-(1-pyrrolidinyl)pentan-1-one;
(42) (NENK) 2-(2-chlorophenyl)-2-(ethylamino)cyclohexanone;
(43) (5-MeO-DMT) 5-methoxy-N,N-dimethyltryptamine;
(44) (AMT) alpha-methyltryptamine;
(45) (3,4-CTMP) methyl 2-(3,4-dichlorophenyl)-2-(piperdin-2-yl);
(46) (AH-7921) 3,4-dichloro-N-((1-(dimethylamino)cyclohexyl)methyl)benzamide;
(47) (4-ethyl-1-naphthalenyl)(1-pentyl-1H-indol-3-yl)methanone;
(48) 2–(2-methylphenyl)–1–(1-pentyl-1H-indol-3-yl)-ethanone;
(49) 1-[1–(2-cyclohexylethyl)–1H-indol-3-yl]-2–(2-methoxyphenyl)-
Ethanone;
(50) [1–(5-fluoropentyl)–1H-indol-3-yl](2-iodophenyl)methanone;
(51) (2-methyl-1-[(1-methylpiperidin-2-yl)methyl]-6-nitro-1H-indol-3-yl)methanone; and
(52) (1-butyl-1H-indol-3-yl)(4-methoxyphenyl)-methanone.
Section 1202, SCHEDULE II ENUMERATED, is amended as follows:
Subsection 1202.1(b) is amended to read as follows:
(b) Opiates: Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, whenever the existence of these isomers, esters, ethers, and salts is possible within the specific chemical designation, dextrorphan excepted:
(1) 4-anilino-N-phenethyl-4-piperidine (ANPP);
(2) Alfentanil;
(3) Alphaprodine;
(4) Anileridine;
(5) Bezitramide;
(6) Bulk Dextropropoxyphene (non-dosage form);
(7) Carfentanil;
(8) Dihydrocodeine;
(9) Dihydroetorphine;
(10) Diphenoxylate;
(11) Fentanyl;
(12) Isomethadone;
(13) Levo-alphacetylmethadol [Some other names: levo-alpha- acetylmethadol, levomethadyl acetate, LAAM];
(14) Levomethorphan;
(15) Levorphanol;
(16) Metazocine;
(17) Methadone;
(18) Methadone-intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane;
(19) Moramide-intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane-carboxylic acid;
(20) Pethidine (meperidine);
(21) Pethidine-Intermediate-A, 4-cyano-1-methyl-4- phenylpiperidine; (Meperidine intermediate-A)
(22) Pethidine-Intermediate-B,ethyl-4-phenylpiperidine-4-carboxylate; (Meperidine intermediate-B);
(23) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine- 4-carboxylic acid; (Meperidine intermediate-C)
(24) Phenazocine;
(25) Piminodine;
(26) Racemethorphan;
(27) Racemorphan;
(28) Remifentanil;
(29) Sufentanil;
(30) Tapentadol;
(31) (Acetylfentanyl) N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide
(32) (Butyrylfentanyl) N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide;
(33) (Fluorobutylfentanyl) N-(4-Fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide;
(34) (Hydroxythiofentanyl) N-( 1-(2-Hydroxy-2-(thiophen-2-yl)ethyl)piperidin-4-yl)-N-pheny1propanamide;
(35) (Isobutyrfentanyl) N-(1-Phenethylpiperidin-4-y1)-N-phenylisobutyramide;
(36) (Ocfentanil) N-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiperidin-4-yl)acetamide; N-(2-Fluorophenyl)-2-methoxy-N-(1-(2-phenylethyl)-4-piperidinyl)acetamide;
(37) 2–(1,3-dimethoxybuta-1,3-dien-2-yl)–3-ethyl-8-methoxy-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quin olizine;
(38) (2a,4aR,6aR,7R,9S,10aS10bR)-methyl-9-acetoxy-2–(furan-3- yl)–6a,10b-dimethyl-4,10-dioxododecahydro-1H- benzo[f]isochromene-7-carboxylate;
(39) 4,5-epoxy-17-methylmorphinan-3-ol;
(40) N-phenyl-N-[1–(2-phenethyl)–4-piperidinyl] acetamide;
(41) N–(1-benzylpiperidin-4-yl)–N–(x-fluorophenyl)-butanamide;
(42) 2-methyl-N-phenyl-N-[1–(1-phenylpropan-2-yl)piperidin-4- yl]propanamide;
(43) 1-cyclohexyl-4–(1,2-diphenylethyl)-piperazine;
(44) N-phenyl-N–(1–(2–(thiophen-2-yl)ethyl)piperidin-4-yl)acetamide;
(45) 4-chloro-N–(1-phenethylpiperidin-2-ylidene)benzenesulfonamide; and
(46) 4-chloro-N–(1–(4-nitrophenethyl)piperidin-2-ylidene)benzenesulfonamide;
Subsection 1202.1(c) is amended to read as follows:
(c) Stimulants: Unless specifically excepted or unless listed in another schedule, any material compound, mixture, or preparation that contains any quantity of the following substances having a stimulant effect on the central nervous system:
(1) Amphetamines, its salts, optical isomers, and salts of its optical isomers;
(2) Biphetamine
(3) Eskatrol;
(4) (Ethylphenidate) ethyl 2-phenyl-2-(piperdin-2-yl)acetate;
(5) Lisdexamfetamine;
(6) Methylphenidate and its salts;
(7) Methamphetamine, its salts, isomers, and salts of isomers; and
(8) Phenmetrazine and its salts;
Section 1204, SCHEDULE IV ENUMERATED, is amended to read as follows:
1204 SCHEDULE IV ENUMERATED
1204.1 The controlled substances listed in this section are included in Schedule IV of the Act unless removed therefrom pursuant to Section 201 of the Act. Schedule IV shall consist of the following controlled substances:
(a) Depressants: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:
(1) Alfaxalone;
(2) Alprazolam;
(3) Barbital;
(4) Bromazepam;
(5) Camazepam;
(6) Chloral betaine;
(7) Chloral hydrate;
(8) Chlordiazepoxide;
(9) Clobazam;
(10) Clonazepam;
(11) Clorazepate;
(12) Clotiazepam;
(13) Cloxazolam;
(14) Delorazepam;
(15) Diazepam;
(16) Dichloralphenazone;
(17) Estazolam;
(18) Ethyl loflazepate;
(19) Ethchlorvynol;
(20) Ethinamate;
(21) Fludiazepam;
(22) Flunitrazepam;
(23) Flurazepam;
(24) Fospropofol;
(25) Halazepam;
(26) Haloxazolam;
(27) Ketazolam;
(28) Loprazolam;
(29) Lorazepam;
(30) Lormetazepam;
(31) Mebutamate;
(32) Medazepam;
(33) Meprobamate;
(34) Methohexital;
(35) Methylphenobarbital (mephobarbital);
(36) Midazolam;
(37) Nimetazepam;
(38) Nitrazepam;
(39) Nordiazepam;
(40) Oxazepam;
(41) Oxazolam;
(42) Paraldehyde;
(43) Petrichloral;
(44) Phenobarbital;
(45) Pinazepam;
(46) Prazepam;
(47) Quazepam;
(48) Temazepam;
(49) Tetrazepam; and
(50) Triazolam;
(b) Fenfluramine: Any material, compound, mixture, or preparation that contains any quantity of the following substances, including its salts, isomers, (whether optical, position, or geometric), and salts of such isomers, whenever the existence of the salts, isomers, and salts of isomers is possible: Fenfluramine;
(c) Stimulants: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position, or geometric), and salts of such isomers whenever the existence of the salts, isomers and salts of isomers is possible within the specific chemical designation:
(1) Cathine;
(2) Clortermine;
(3) Dexfenfluramine;
(4) Diethylpropion;
(5) Fencamfamin;
(6) Fenproporex;
(7) Lorcaserin;
(8) Mazindol;
(9) Mefenorex;
(10) Modafinil;
(11) Pemoline (including organometallic complexes and chelates thereof);
(12) Phentermine;
(13) Pipradrol;
(14) Sibutramine; and
(15) SPA;
(d) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation that contains any quantity of the following substances, including its salts:
(1) Butorphanol;
(2) Dextropropoxyphene (Alpha-(+)-4-demethylamino-1), 2-diphenyl-1-3-methyl-2-propionoxybutane; and
(3) Pentazocine;
(e) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing limited quantities of any of the following narcotic drugs, or any salts thereof of not more than one (1) milligram of difenoxin and not less than twenty-five (25) micrograms of atropine sulfate per dosage unit;
(f) Carisoprodol;
(g) Zaleplon;
(h) Zolpidem;
(i) Zopiclone;
(j) Suvorexant;
(k) Tramadol;
(l) Brotizolam; 3-(2- bromophenyl)-4-[(3- chlorophenyl)methylideneamino]-1H-1,2,4-triazole-5-thione;
(m) Vinylbital; (Vinylbitone; Vinylbitalum;);
(n) Mesocarb;
(o) Dezocine;
(p) Allobarbital; Allobarbitone;
(q) (Phenazepam) 7-bromo-5-(2-chlorophenyl)-1,3,dihydro-2H-1,4-benzodiazepin-2-one;
(r) 4–(2-chlorophenyl)–2-ethyl-9-methyl-6H-thieno-[3,2- f][1,2,4]triazolo[4,3-a][1,4]diazepine(#) 7-bromo-5–(2-chlorophenyl)–1H-benzo[e][1,4]diazepin-2(3H)-one(#) 8-bromo-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3a][1,4]benzodiazepine;
(s) 3-methyl-6-[3–(trifluoromethyl)phenyl][1,2,4]triazol[4,3-b]pyridazine; and
(t) 6–(5-chloro-2-pyridyl)–6,7-dihydro-7-oxo-5H-pyrrolo[3,4- b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate.
Comments on the emergency and proposed rules should be sent in writing to the Department of Health, Office of the General Counsel, 5th Floor, 899 North Capitol Street, N.E., Washington, D.C. 20002, not later than thirty (30) days after the date of publication of this notice in the D.C. Register. Copies of the proposed rules may be obtained Monday through Friday, except holidays, between the hours of 8:15 A.M. and 4:45 P.M. at the same address. Questions concerning the rulemaking should be directed to Angli Black, Administrative Assistant, at Angli.Black@dc.gov or (202) 442-5977.
